Human Milk Oligosaccharides Shape Infant Gut Microbiome Well Past Breastfeeding
A large cohort study finds HMOs have age-dependent, structure-specific effects on infant gut bacteria that persist to 13 months.
Summary
A Finnish population-based study of over 500 infants found that specific human milk oligosaccharides (HMOs) — bioactive sugars in breast milk — shape the infant gut microbiome in ways that differ by the infant's age and the exact HMO structure. At 3 months, two sialylated HMOs (DSLNT and LSTb) were most influential, while a different HMO (FDSLNH) dominated associations at 13 months, even after breastfeeding had ended. Maternal secretor status — a genetic trait affecting which HMOs a mother produces — also influenced gut microbiome diversity. Interestingly, no single HMO fully corrected the altered microbiome patterns seen in cesarean-born infants, though secretor mothers appeared to partially buffer these effects. The findings suggest HMOs have lasting, structure-specific impacts on early gut colonization with potential long-term health implications.
Detailed Summary
Early gut microbiome colonization is a critical window for lifelong health, influencing immune development, metabolism, and disease risk. Human milk oligosaccharides (HMOs) — complex sugars abundant in breast milk — are known to selectively feed beneficial gut bacteria, but how specific HMO structures affect the microbiome at different infant ages, and whether they can correct dysbiosis in cesarean-born infants, has remained unclear.
This population-based cohort study from Finland analyzed fecal samples from 517 infants at 3 months and 522 at 13 months, alongside breast milk samples collected at 3 months. Researchers quantified 19 individual HMOs using high-performance liquid chromatography and profiled gut bacteria via 16S rRNA sequencing. Statistical methods including Dirichlet Multinomial Mixtures clustering, PERMANOVA, and multinomial logistic regression were used to link HMO profiles to gut microbiome community types, diversity, and specific bacterial genera.
Key findings revealed that HMO effects are both age-dependent and structure-specific. At 3 months, the sialylated HMOs disialyllacto-N-tetraose (DSLNT) and lacto-N-sialyllactose b (LSTb) showed the strongest associations with gut microbiome composition. By 13 months — well after most breastfeeding had likely tapered — fucodisialyllacto-N-hexaose (FDSLNH) emerged as the dominant HMO associated with multiple microbiome metrics. Maternal secretor status, which determines the types of fucosylated HMOs produced, was linked to reduced Shannon diversity at 3 months and influenced cesarean-related microbiome patterns.
Regarding cesarean delivery, no individual HMO fully restored the microbiome to vaginal-birth patterns, but infants of non-secretor mothers showed more pronounced cesarean-associated dysbiosis, suggesting secretor-status HMOs offer partial protection.
Clinically, these findings reinforce the importance of breastfeeding and suggest that HMO composition — not just quantity — matters for infant gut health. Future infant formula development targeting specific HMO structures may better support microbiome development. Limitations include reliance on the abstract alone and the observational design, which precludes causal conclusions.
Key Findings
- DSLNT and LSTb HMOs most strongly shaped gut microbiome composition at 3 months of age.
- FDSLNH was the dominant HMO associated with gut microbiome metrics at 13 months, post-breastfeeding.
- HMO effects on the infant gut microbiome are age-dependent and structure-specific, not uniform.
- No single HMO fully corrected cesarean-related gut dysbiosis, but secretor mothers partially buffered it.
- Maternal secretor status independently influenced infant gut microbiome diversity at 3 months.
Methodology
Population-based Finnish cohort study with fecal samples from 517 infants at 3 months and 522 at 13 months, paired with breast milk HMO quantification (19 HMOs via HPLC). Gut microbiome profiled by 16S rRNA sequencing; community types identified via Dirichlet Multinomial Mixtures clustering with PERMANOVA and regression analyses for associations.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting assessment of methodological detail and effect sizes. The observational cohort design prevents causal inference about HMO effects on the microbiome. Confounders such as antibiotic use, diet, and gestational age may not be fully accounted for.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.